CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Alpha Cognition Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Alpha Cognition Inc
c/o 1200 - 750 West Pender Street
Phone: (604) 564-9244p:604 564-9244 Vancouver, BC  V6C 2T8  Canada Ticker: ACOGACOG

Business Summary
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Chairman of the Board LenMertz 3/18/2021 3/18/2021
Chief Executive Officer, Director MichaelMcfadden 3/28/2022 4/12/2021
Interim Chief Financial Officer, Vice President - Finance and Accounting HenryDu 10/21/2024 10/21/2024
6 additional Officers and Directors records available in full report.

Business Names
Business Name
ACOG
Alpha Cognition Canada Inc.
Alpha Cognition USA Inc.

General Information
Number of Employees: 52 (As of 12/31/2024)
Outstanding Shares: 16,019,788 (As of 1/10/2025)
Stock Exchange: NASD


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, May 6, 2025